Paper Details

  1. Home
  2. Paper Details

Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder.

Author: CutlerAndrew J, MaleticVladimir, MattinglyGregory W

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This review discusses the role of gamma-aminobutyric acid (GABA) and neuroactive steroids (NASs) in major depressive disorder (MDD). GABA is an inhibitory neurotransmitter that works through GABA<sub>A</sub> receptors, and NASs are positive allosteric modulators (PAMs) of GABA<sub>A</sub> receptors. The review discusses preclinical and clinical data that support the association of depression with GABAergic system defects. It also discusses NASs approved or in clinical development for depression, including brexanolone, zuranolone, and PH10.
Paper Details　
Original Abstract of the Article :
The pathophysiology of major depressive disorder (MDD) is thought to result from impaired connectivity between key brain networks. Gamma-aminobutyric acid (GABA) is the key inhibitory neurotransmitter in the brain, working primarily via GABA<sub>A</sub> receptors, with an important role in virtually...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293235/

データ提供：米国国立医学図書館（NLM）

Unraveling the Mysteries of Neuroactive Steroids and GABA in Depression

Depression, a complex and debilitating mental health condition, affects millions worldwide. This review delves into the intricate world of neuroactive steroids (NASs) and their role in depression. NASs, like certain types of steroids found in our bodies, influence brain activity by modulating GABAA receptors. The authors explore the intricate relationship between depression and GABAergic neurotransmission, the system that regulates brain activity through the neurotransmitter GABA. They discuss the potential of NASs as effective treatment options for depression, particularly those targeting dysregulated GABAergic neurotransmission.

NASs: Potential New Players in Depression Treatment

The study highlights the potential of NASs as novel treatments for depression, with a focus on their ability to modulate GABAergic neurotransmission. Brexanolone, an intravenous NAS, has been approved by the U.S. Food and Drug Administration for the treatment of postpartum depression. Other NASs, like zuranolone and PH10, are currently undergoing clinical trials for their potential to alleviate depressive symptoms.

Hope for New Treatments for Depression

This review offers a glimmer of hope for those struggling with depression. By exploring the potential of NASs and their impact on GABAergic neurotransmission, researchers are paving the way for new and effective treatments with potentially rapid and sustained antidepressant effects. The study emphasizes the importance of continued research in this area to address the unmet need for novel and effective therapies for depression.

Dr.Camel's Conclusion

Think of depression as a dense fog blanketing the desert of your mind. NASs, like a powerful wind, can help clear this fog by restoring balance in the GABAergic system, the brain's intricate network of communication. The researchers are like skilled desert navigators, guiding us through this complex landscape of mental health, seeking new treatments to illuminate the path to recovery.

Date :
  1. Date Completed 2023-06-28
  2. Date Revised 2023-07-01
Further Info :

Pubmed ID

37365161

DOI: Digital Object Identifier

PMC10293235

Related Literature

Article Analysis
・Effects of zuranolone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.